超敏血清干扰素α检测可识别SLE缓解期复发高危患者
研究纳入254例按DORIS分类处于缓解期的SLE患者,用超敏单分子阵列数字免疫分析检测基线血清IFN-α并随访1年。26%患者IFN-α异常升高,与RNP、dsDNA、Ro/SSA60抗体阳性及年轻相关;基线IFN-α升高和缓解持续时间独立关联更短复发时间,而低C3和抗dsDNA抗体无此关联。
要点
- 缓解期SLE患者中26%血清IFN-α异常升高
- 基线IFN-α升高独立预测更短复发时间
- 超敏数字免疫分析可识别临床缓解但复发高危亚组
核心结论
- 超敏数字免疫分析直接检测血清IFN-α可识别临床缓解但复发风险更高的SLE患者亚组。
研究设计与样本
- 纳入254例按DORIS分类处于缓解期的SLE患者,基线检测血清IFN-α并随访1年。
- 采用超敏单分子阵列数字免疫分析测定生理浓度细胞因子,用Kaplan-Meier和Cox回归分析复发时间及基线相关因素。
主要发现
- 26%缓解期患者血清IFN-α水平异常升高。
- IFN-α升高与RNP、dsDNA、Ro/SSA60特异性抗体阳性及年轻年龄相关。
- 基线IFN-α升高和缓解持续时间独立关联更短复发时间。
- 低补体C3和抗dsDNA抗体与复发时间无独立关联。
关键数值与推荐
- 缓解按DORIS分类定义,复发按SELENA-SLEDAI Flare Index定义。
临床怎么用
- 对临床缓解的SLE患者可用超敏数字免疫分析检测血清IFN-α以分层复发风险。
- 基线IFN-α升高且缓解持续时间短者可能需更密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Maintenance of remission has become central in the management of systemic lupus erythematosus (SLE). The importance of interferon-alpha (IFN-α) in the pathogenesis of SLE notwithstanding, its expression in remission has been poorly studied as yet. To study its expression in remission and its prognostic value in the prediction of a disease relapse, serum IFN-α levels were determined using an ultrasensitive single-molecule array digital immunoassay which enables the measurement of cytokines at physiological concentrations. METHODS: A total of 254 SLE patients in remission, according to the Definition of Remission in SLE classification, were included in the study. Serum IFN-α concentrations were determined at baseline and patients were followed up for 1 year. Lupus flares were defined according to the Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index Flare Index, whereas the Kaplan-Meier analysis and Cox regression analysis were used to estimate the time to relapse and to identify baseline factors associated with time to relapse, respectively. RESULTS: Of all patients in remission, 26% displayed abnormally high IFN-α serum levels that were associated with the presence of antibodies specific for ribonucleoprotein (RNP), double stranded (ds)DNA and Ro/SSA60, as well as young age. Importantly, elevated-baseline IFN-α serum levels and remission duration were associated in an independent fashion, with shorter time to relapse, while low serum levels of complement component 3 and anti-dsDNA Abs were not. CONCLUSION: Direct serum IFN-α assessment with highly sensitive digital immunoassay permits clinicians to identify a subgroup of SLE patients, clinically in remission, but at higher risk of relapse.
引用
- Mathian A, Mouries-Martin S, Dorgham K, et al. Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis. 2019. PMID: 31570366. doi:10.1136/annrheumdis-2019-215571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。